HilleVax, Inc. (HLVX)

NASDAQ: HLVX · Delayed Price · USD
9.67
-0.44 (-4.35%)
At close: May 25, 2022 4:00 PM
9.83
0.16 (1.65%)
After-hours:May 25, 2022 4:55 PM EDT
Market Cap323.24M
Revenue (ttm)n/a
Net Income (ttm)-102.41M
Shares Out33.43M
EPS (ttm)-3.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume220,392
Open9.83
Previous Close10.11
Day's Range8.82 - 10.06
52-Week Range8.82 - 20.95
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About HLVX

HilleVax is a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines. Our initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. It is estimated that norovirus causes nearly 700 million cases of illness and more than 200,000 deaths worldwide per year, as well as significant additional economic and social burden. To date, HIL-214 has been studied in nine clinical trials conducted...

IndustryBiotechnology
IPO DateApr 29, 2022
CEORob Hershberg, M.D., Ph.D.
Employees31
Stock ExchangeNASDAQ
Ticker SymbolHLVX
Full Company Profile

Financial Performance

Financial Statements

News

HilleVax Announces Pricing of Upsized Initial Public Offering

HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the pricing of its upsized initial public offering...

3 weeks ago - GLOBE NEWSWIRE

Norovirus vaccine developer HilleVax files for a $100 million IPO

HilleVax, a Phase 2 biotech developing a novel norovirus vaccine in-licensed from Takeda, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - Renaissance Capital

HilleVax IPO Registration Document (S-1)

HilleVax has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC